La Jolla Pharmaceutical's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of La Jolla Pharmaceutical (LJPC) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: La Jolla Pharmaceutical vs Its Competitors
- TTM: Trailing 12-month revenue of 46M vs 22M combined for its competitors (67.6% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-9.3% annualized vs trailing 12 months).
- Peer revenue share: La Jolla Pharmaceutical accounted for 100.0% of combined revenue among its tracked peer group, up from 98.8% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LJPC Sales vs. its Competitors, Q2 2022
La Jolla Pharmaceutical generated 100.00 % of the combined sales of its peer group, up from 98.75 % a year earlier.
API endpoints for this dataset
La Jolla Pharmaceutical vs. its Competitors, Q2 2022
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in La Jolla Pharmaceutical reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across La Jolla Pharmaceutical and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| La Jolla Pharmaceutical Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across La Jolla Pharmaceutical's competitor groups requires a Commercial License.
For context: the Biotechnology & Pharmaceuticals industry grew revenue 20.8% year over year, combined, vs -34.4% for La Jolla Pharmaceutical. La Jolla Pharmaceutical's share of combined industry revenue moved from 0.04% to 0.02%, a loss of 0.02 percentage points.
La Jolla Pharmaceutical's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| La Jolla Pharmaceutical Company | Yes | No | No | No |
| Competitors combined (1) | - | - | - | |
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LJPC Stock Performance relative to its Competitors
LJPC Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Capricor Therapeutics inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for La Jolla Pharmaceutical's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of La Jolla Pharmaceutical Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 La Jolla Pharmaceutical Company |
199.54 | 46.49 |
 Capricor Therapeutics inc |
516.91 | 22.27 |
| SUBTOTAL | 716.45 | 68.76 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on La Jolla Pharmaceutical Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
La Jolla Pharmaceutical's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| La Jolla Pharmaceutical Company | 200 | - | - |
| Capricor Therapeutics inc | 517 | 96,409 | -496,077 |
| PEERS TOTAL | 517 | 96,409 | -496,077 |
La Jolla Pharmaceutical's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Biotechnology & Pharmaceuticals industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (160 companies). See the full Biotechnology & Pharmaceuticals industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 82.91 % | 34.84 % (avg) | +48.1 pp |
| Operating Margin | -5.53 % | industry median | +464.2 pp |
| EBITDA Margin | 22.97 % | -2.62 % (avg) | +25.6 pp |
| Capital Intensity (Capex / Revenue) | 0.02 % | 8.89 % (avg) | -8.9 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
La Jolla Pharmaceutical's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 27.3x | - |
| EV / EBITDA | 7.3x | 17.0x | -9.7x |
| P/B | -1.8x | 5.1x | -6.9x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -18.37 % | -11.80 % (avg) | -6.57 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
La Jolla Pharmaceutical's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2014 | 2015 | 2017 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | 129.26 % | 44.96 % | 126.58 % |
| Operating Margin | - | - | - | - | - | 28.83 % |
| Return on Invested Capital | -38.94 % | -24.89 % | -44.65 % | -95.41 % | -4,695.45 % | 159.42 % |
| P/E | - | - | - | - | - | 7.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
La Jolla Pharmaceutical's Strategic Group Map
La Jolla Pharmaceutical is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
La Jolla Pharmaceutical's trailing-12-month revenue growth of -33.8% and operating margin of -5.5% compares with an average of -3.1% growth and -5.0% margin across its 8 closest peers by combined growth, margin and ROIC -- La Jolla Pharmaceutical sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
La Jolla Pharmaceutical's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.02 % vs industry average 8.89 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on La Jolla Pharmaceutical's dedicated Suppliers and Customers pages, not here.
La Jolla Pharmaceutical's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
La Jolla Pharmaceutical falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
La Jolla Pharmaceutical's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 464.2 points above the industry median.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-9.3% annualized vs trailing 12 months).
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
La Jolla Pharmaceutical's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| La Jolla Pharmaceutical Company | 2.81 | 3.97 | - |
| Capricor Therapeutics inc | 3.46 | 6.60 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
La Jolla Pharmaceutical's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| La Jolla Pharmaceutical Company | Q2 2022 | -34.3 % | -34.2 % |
| Capricor Therapeutics inc | Q1 2026 | - | - |
| PEERS TOTAL | -34.3 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
La Jolla Pharmaceutical's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| La Jolla Pharmaceutical Company | Q2 2022 | -21.6 % | - |
| Capricor Therapeutics inc | Q1 2026 | - | +471.6 % |
La Jolla Pharmaceutical's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| La Jolla Pharmaceutical Company | 4.00% | 4.79% | - |
| Capricor Therapeutics inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
La Jolla Pharmaceutical's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| La Jolla Pharmaceutical Company | - | 4.29 |
| Capricor Therapeutics inc | - | 23.21 |
| PEERS AVERAGE | - | 10.42 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.